127 related articles for article (PubMed ID: 4462871)
1. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
Castaigne P; Rondot P; Taberlet A; Baumann N
Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
[No Abstract] [Full Text] [Related]
2. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
Rabadeau Dumas JL; Rondot P; Cardon P
Therapie; 1977; 32(2):161-72. PubMed ID: 898124
[No Abstract] [Full Text] [Related]
3. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Rondot P
Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
[No Abstract] [Full Text] [Related]
4. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
[No Abstract] [Full Text] [Related]
5. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Puca FM; Megna GF; Masi G; Specchio LM
Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
[No Abstract] [Full Text] [Related]
6. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
[No Abstract] [Full Text] [Related]
7. [Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
Carolei A; Casacchi M; Fazio C
Clin Ter; 1977 Jan; 80(2):181-9. PubMed ID: 844268
[No Abstract] [Full Text] [Related]
8. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
[TBL] [Abstract][Full Text] [Related]
9. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
Chouza C; Romero S; Gomensoro JB
Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
[No Abstract] [Full Text] [Related]
10. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
11. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
Boismare F; Boquet J; Lefrançois J; Le Poncin M
Agressologie; 1977; 18(5):285-6. PubMed ID: 602991
[No Abstract] [Full Text] [Related]
12. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
[No Abstract] [Full Text] [Related]
13. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
14. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
[No Abstract] [Full Text] [Related]
15. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg CA; Gachoud JP
Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
[TBL] [Abstract][Full Text] [Related]
16. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
[No Abstract] [Full Text] [Related]
17. [The L-dopa test in Parkinson's disease].
Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Kamenetskiĭ VK
Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
[No Abstract] [Full Text] [Related]
19. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
[No Abstract] [Full Text] [Related]
20. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients.
Matussek N; Angst J; Benkert O; Gmür M; Papousek M; Rüther E; Woggon B
Adv Biochem Psychopharmacol; 1974; 11(0):399-404. PubMed ID: 4602669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
